as 11-21-2024 4:00pm EST
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
Founded: | 1983 | Country: | United States |
Employees: | N/A | City: | BURLINGTON |
Market Cap: | 2.0B | IPO Year: | 2006 |
Target Price: | $92.83 | AVG Volume (30 days): | 139.9K |
Analyst Decision: | Buy | Number of Analysts: | 7 |
Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
EPS: | 1.82 | EPS Growth: | 49.21 |
52 Week Low/High: | $51.70 - $106.99 | Next Earning Date: | 10-31-2024 |
Revenue: | $213,029,000 | Revenue Growth: | 14.81% |
Revenue Growth (this year): | 16.04% | Revenue Growth (next year): | 9.62% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Ross Bridget A | LMAT | Director | Nov 15 '24 | Sell | $101.47 | 3,750 | $380,512.50 | 2,278 | |
SHADAN MARTHA | LMAT | Director | Nov 13 '24 | Sell | $103.38 | 1,466 | $151,547.27 | 1,700 |
LMAT Breaking Stock News: Dive into LMAT Ticker-Specific Updates for Smart Investing
Argus Research
9 days ago
Argus Research
16 days ago
Simply Wall St.
19 days ago
GlobeNewswire
20 days ago
GuruFocus.com
20 days ago
MT Newswires
21 days ago
Zacks
21 days ago
Associated Press Finance
21 days ago
The information presented on this page, "LMAT LeMaitre Vascular Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.